Groups Uniting To Grow Global Regenerative Medicine Sector
This article was originally published in PharmAsia News
South Korea, the U.S. and Japan are among the leading countries involved in the commercialization of stem cell therapies, with Japan’s Ministry of Economy, Trade and Industry (METI) estimating that the global regenerative medicines (RM) industry will grow strongly to reach a massive JPY53 trillion ($449 billion) by 2050. Groups in all three countries are now working closely to overcome the challenges in the sector, a recent conference in South Korea heard.
You may also be interested in...
Going public via an IPO or being acquired are two ways that Asian biotech companies can grow their business, and some of the issues involved in both approaches come under discussion at a panel session at a recent conference in Singapore.
A China-based IVD company, spun out of an Australian medical research institute, is seeking investors to support its plans for the 2018 launch its first two point-of-care tests for patients with infectious diseases including HIV and viral hepatitis.
Speakers from the legal, corporate and contract research sectors discussed the fast-moving changes that are impacting the legal and regulatory aspects of doing business in China at the recent AusBiotech conference in Melbourne, providing a broad range of advice for Australian and other pharma and biotech companies wanting to enter the rapidly expanding Chinese life sciences market.